Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
![NCT07664397 [89Zr]DFO-YS5 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
Latest Hotspot
8 min read
NCT07664397 [89Zr]DFO-YS5 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664397 clinical trial report covering [89Zr]DFO-YS5, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664176 Nivolumab Ependymoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664176 clinical trial report covering Nivolumab, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664631 Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamp Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664631 clinical trial report covering Amphetamine Aspartate/Amphetamine Sulfate/Dextroamphetamine Saccharate/Dextroamp, Phase 1, endpoints, sponsor, g
Latest Hotspot
8 min read
NCT07669012 Dexmedetomidine Hydrochloride Sedation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07669012 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 1, endpoints, sponsor, geography, readout timing and development white spac
Latest Hotspot
8 min read
NCT07667621 Rimegepant Sulfate Migraine With Aura Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667621 clinical trial report covering Rimegepant Sulfate, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07668557 Fludarabine Phosphate Refractory acute myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668557 clinical trial report covering Fludarabine Phosphate, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07668999 ZYG24004 Tinea Pedis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668999 clinical trial report covering ZYG24004, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262404 QM103 BCMA Positive Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262404 clinical trial report covering QM103, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262322 SBK007 Rhinitis, Allergic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262322 clinical trial report covering SBK007, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262482 GA-001 Retinitis Pigmentosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
CTR20262482 clinical trial report covering GA-001, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667868 BP-2202 (BrightPath) Relapse multiple myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667868 clinical trial report covering BP-2202 (BrightPath), Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667842 D3L-002 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07667842 clinical trial report covering D3L-002, Phase 1, endpoints, sponsor, geography, readout timing and development white space.